Page last updated: 2024-11-04

rolipram and Anemia

rolipram has been researched along with Anemia in 1 studies

Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.

Research Excerpts

ExcerptRelevanceReference
"This study was designed to evaluate hemorheological changes in patients with cerebrovascular disease (CVD) and peripheral arterial disease (PAD) after 4 weeks of pentoxifylline therapy as well as to study red blood cell microrheological variables after the cell incubation with pentoxifylline and some phosphodiesterase (PDE) activity inhibitors."5.15Macro- and microrheological parameters of blood in patients with cerebral and peripheral atherosclerosis: the molecular change mechanisms after pentoxifylline treatment. ( Bulaeva, SV; Miloradov, MJ; Muravyov, AV; Tikhomirova, IA; Uzikova, EV; Zamishlayev, AV, 2011)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Muravyov, AV1
Bulaeva, SV1
Tikhomirova, IA1
Zamishlayev, AV1
Uzikova, EV1
Miloradov, MJ1

Trials

1 trial available for rolipram and Anemia

ArticleYear
Macro- and microrheological parameters of blood in patients with cerebral and peripheral atherosclerosis: the molecular change mechanisms after pentoxifylline treatment.
    Clinical hemorheology and microcirculation, 2011, Volume: 49, Issue:1-4

    Topics: 1-Methyl-3-isobutylxanthine; Adult; Aged; Anemia; Blood Transfusion; Erythrocytes; Erythropoietin; F

2011